{"product_id":"recombinant-human-cyclin-dependent-kinase-7-cdk7-bhp10509648","title":"Recombinant Human Cyclin-dependent kinase 7 (CDK7)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eRecombinant Human Cyclin-dependent kinase 7 (CDK7) is a recombinant protein reagent derived from Homo sapiens (Human) and produced in E.coli. It is commonly used to support Cell Biology research by enabling enzyme activity assays, kinetics\/structure–function studies and inhibitor or substrate screening in controlled in vitro settings.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eExpressed region:\u003c\/strong\u003e 1-346aa. Region selection can focus on functional domains, improve solubility, or isolate interaction surfaces for targeted studies.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli. Expression host can influence folding and the presence\/absence of post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eTag \/ fusion:\u003c\/strong\u003e Tag-Free. Tags can support purification and detection; evaluate potential tag effects when studying sensitive interactions.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight (reported):\u003c\/strong\u003e 39.2 kDa. Apparent size may vary with tags, processing, and gel conditions.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWhen comparing results across batches or platforms, interpret signals in the context of construct design (region, tags) and expression host, especially for modification-dependent interactions.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eThe gene commonly associated with this target is \u003cstrong\u003eCDK7\u003c\/strong\u003e. CDK7 refers to a protein target that is studied across multiple biological contexts; annotations and nomenclature can vary by species and isoform. This product corresponds to the Homo sapiens (Human) sequence context, which can be important when comparing homologs or orthologs across model systems. For curated functional annotations, domains, and sequence features, consult primary databases (e.g., UniProt\/NCBI) and the recent literature for the specific organism and isoform.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eUsing recombinant proteins to enable quantitative binding measurements and reagent benchmarking.\u003c\/li\u003e \u003cli\u003eStudying domain- and isoform-specific effects in pathway models and interaction networks.\u003c\/li\u003e \u003cli\u003eDeveloping robust, reproducible assays that connect molecular readouts to cellular phenotypes.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cstrong\u003eRelevance:\u003c\/strong\u003e Serine\/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1\/cyclin-B during G2-M transition, and for activation of CDK2\/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5\/SUPT5H, SF1\/NR5A1, POLR2A, p53\/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B\/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53\/TP53 activation by phosphorylation, but is inactivated in turn by p53\/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.\u003c\/p\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eEnzyme activity assays and kinetics measurements with defined substrates\/cofactors.\u003c\/li\u003e \u003cli\u003eInhibitor, activator, or substrate screening in biochemical assay formats.\u003c\/li\u003e \u003cli\u003eStructure–function analysis to interpret how sequence changes impact catalytic performance.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn quantitative assay development, changes in binding or activity readouts are typically interpreted relative to appropriate negative\/positive controls and, where possible, orthogonal assay formats that support the same conclusion.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eRecombinant constructs may represent a defined region (domain) rather than the full-length protein; interpret results in the context of the expressed region.\u003c\/li\u003e \u003cli\u003eTag or fusion elements can aid purification and detection but may influence binding surfaces or oligomerization; consider tag controls when relevant.\u003c\/li\u003e \u003cli\u003eSpecies and isoform differences can affect interaction partners and post-translational modifications; align experimental controls to the intended biological context.\u003c\/li\u003e \u003cli\u003eE. coli expression can limit eukaryotic post-translational modifications; for modification-dependent biology, interpret results accordingly.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry for P50613 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/P50613\/entry - NCBI Gene search (CDK7) — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=CDK7 - PubMed search (CDK7) — NCBI — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=CDK7 - RCSB PDB search (CDK7) — RCSB PDB — https:\/\/www.rcsb.org\/search?query=CDK7 - Reactome Pathway Browser — Reactome — https:\/\/reactome.org\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53065295135085,"sku":"CSB-EP005075HU-1MG","price":2228.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53065441411437,"sku":"CSB-EP005075HU-100UG","price":646.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53065441444205,"sku":"CSB-EP005075HU-20UG","price":422.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP005075HU-SDS.jpg?v=1772476489","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-cyclin-dependent-kinase-7-cdk7-bhp10509648","provider":"BioHippo","version":"1.0","type":"link"}